Bipolar Disorders Treatment Market Analysis (2020-2027)
Bipolar disorder is a lifelong disease, which can be managed with proper medication. The medications used to manage bipolar disorder symptoms include mood stabilizers and atypical antipsychotics. Mood stabilizers such as lithium and other drugs are used for the treatment of bipolar disorders by suppressing mood swings such as mania and depression. Cariprazine is an atypical antipsychotic drug indicated for the treatment of depressive episodes associated with bipolar I disorder in adults. Antidepressant medications are also prescribed to treat depressive episodes in bipolar disorder. Antidepressants combined with mood stabilizers are indicated to prevent triggering of maniac episode in patients with bipolar disorder.
Market Dynamics
The increasing adoption of inorganic growth strategies such as mergers, agreements, and collaborations by key players operating in the market are expected to propel the market growth over the forecast period. For instance, in July 2019, Gedeon Richter plc, entered into an exclusive license agreement with Hikma Pharmaceuticals Plc. to commercialize cariprazine, a novel antipsychotic drug, in certain Middle East and North African or MENA markets. Moreover, earlier in August 2016, Gedeon RichterPlc. and Recordati signed an exclusive license agreement to commercialize cariprazine, a novel atypical antipsychotic drug in Western Europe, Algeria, and Tunisia.
Key features of the study:
· This report provides in-depth analysis of the global bipolar disorder treatment market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2019–2027), considering 2019 as the base year
· It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
· This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
· It profiles key players in the global bipolar disorder treatment market based on the following parameters – company overview, financial performance, Device portfolio, market presence, distribution strategies, key developments, strategies, and future plans
· Key companies covered as a part of this study include Takeda Pharmaceutical Company Limited, Pfizer, Inc., Allergan plc, Otsuka Holdings Co. Ltd., Johnson & Johnson, Eli Lilly and Company, GlaxoSmithKline plc, AstraZeneca Plc, Novartis International AG, AbbVie Inc., H. Lundbeck A/S, Minerva Neurosciences, Sumitomo Dainippon Pharma Co., Ltd., Intra-Cellular Therapies Inc., Gedeon Richter Plc., and Indivior PLC
· Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future device launches, drug class up-gradation, market expansion, and marketing tactics
· The global bipolar disorder treatment market report caters to various stakeholders in this industry including investors, suppliers, device manufacturers, distributors, new entrants, and financial analysts
· Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global bipolar disorder treatment market
Detailed Segmentation:
· Global Bipolar Disorder Treatment Market, By Drug Class:
o Antipsychotics
o Antidepressants
o Mood Stabilizers
o Anti-anxiety Drugs and Others
· Global Bipolar Disorder Treatment Market, By Distribution Channel:
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
· Global Bipolar Disorder Treatment Market, By Region:
o North America
§ By Drug Class:
§ Antipsychotics
§ Antidepressants
§ Mood Stabilizers
§ Anti-anxiety Drugs and Others
§ By Distribution Channel:
§ Hospital Pharmacies
§ Retail Pharmacies
§ Online Pharmacies
§ By Country:
§ U.S.
§ Canada
o Latin America
§ By Drug Class:
§ Antipsychotics
§ Antidepressants
§ Mood Stabilizers
§ Anti-anxiety Drugs and Others
§ By Distribution Channel:
§ Hospital Pharmacies
§ Retail Pharmacies
§ Online Pharmacies
§ By Country:
§ Brazil
§ Mexico
§ Argentina
§ Rest of Latin America
o Europe
§ By Drug Class:
§ Antipsychotics
§ Antidepressants
§ Mood Stabilizers
§ Anti-anxiety Drugs and Others
§ By Distribution Channel:
§ Hospital Pharmacies
§ Retail Pharmacies
§ Online Pharmacies
§ By Country:
§ Germany
§ U.K.
§ France
§ Italy
§ Spain
§ Russia
§ Rest of Europe
o Asia Pacific
§ By Drug Class:
§ Antipsychotics
§ Antidepressants
§ Mood Stabilizers
§ Anti-anxiety Drugs and Others
§ By Distribution Channel:
§ Hospital Pharmacies
§ Retail Pharmacies
§ Online Pharmacies
§ By Country:
§ China
§ India
§ Japan
§ Australia
§ South Korea
§ ASEAN
§ Rest of Asia Pacific
o Middle East
§ By Drug Class:
§ Antipsychotics
§ Antidepressants
§ Mood Stabilizers
§ Anti-anxiety Drugs and Others
§ By Distribution Channel:
§ Hospital Pharmacies
§ Retail Pharmacies
§ Online Pharmacies
§ By Country:
§ GCC
§ Israel
§ Rest of Middle East
o Africa
§ By Drug Class:
§ Antipsychotics
§ Antidepressants
§ Mood Stabilizers
§ Anti-anxiety Drugs and Others
§ By Distribution Channel:
§ Hospital Pharmacies
§ Retail Pharmacies
§ Online Pharmacies
§ By Country/Region:
§ South Africa
§ Central Africa
§ North Africa
· Company Profiles
o Takeda Pharmaceutical Company Limited*
§ Company Overview
§ Material Portfolio
§ Financial Performance
§ Key Highlights
§ Market Strategies
o Pfizer, Inc.
o Allergan plc
o Otsuka Holdings Co. Ltd.
o Johnson & Johnson
o Eli Lilly and Company
o GlaxoSmithKline plc
o AstraZeneca Plc
o Novartis International AG
o AbbVie Inc.
o Lundbeck A/S
o Minerva Neurosciences
o Sumitomo Dainippon Pharma Co., Ltd.
o Intra-Cellular Therapies Inc.
o Gedeon Richter Plc.
o Indivior PLC
“*” marked represents similar segmentation in other categories in the respective section.
https://www.coherentmarketinsights.com/insight/request-sample/2605
https://www.coherentmarketinsights.com/insight/request-pdf/2605
Click here to buy: https://www.coherentmarketinsights.com/insight/buy-now/2605
CMI Services:https://www.coherentmarketinsights.com/services
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions.
What we provide:
· Customized Market Research Services
· Industry Analysis Services
· Business Consulting Services
· Market Intelligence Services
· Long term Engagement Model
· Country Specific Analysis
Mr. Shah
Coherent Market Insights Pvt. Ltd.
Address: 1001 4th ave, #3200 Seattle, WA 98154, U.S.
Phone: +1-206-701-6702
Email :sales@coherentmarketinsights.com
Reference/Source: https://www.coherentmarketinsights.com/market-insight/bipolar-disorders-treatment-market-2605